Journal Home
Search for

Volume 8, Issue 7, Pages 573-582 (July 2007)


View previous. 10 of 13 View next.

Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy

Michael F. FlemingCorresponding Author Informationemail address, Stacey L. Balousek, Cynthia L. Klessig, Marlon P. Mundt, David D. Brown

Received 6 July 2006; received in revised form 20 February 2007; accepted 27 February 2007. published online 14 May 2007.

Abstract 

The primary goal of this paper was to present a comprehensive picture of substance use disorders in a sample of patients receiving opioid therapy from their primary care physician. A second goal was to determine the relation of positive urine screens and aberrant drug behaviors to opioid use disorders. The study recruited 801 adults receiving daily opioid therapy from the primary care practices of 235 family physicians and internists in 6 health care systems in Wisconsin. The 6 most common pain diagnoses were degenerative arthritis, low back pain, migraine headaches, neuropathy, and fibromyalgia. The point prevalence of current (DSM-IV criteria in the past 30 days) substance abuse and/or dependence was 9.7% (n = 78) and 3.8% (30) for an opioid use disorder. A logistic regression model found that current substance use disorders were associated with age between 18 and 30 (OR = 6.17: 1.99 to 19.12), severity of lifetime psychiatric disorders (OR = 6.17; 1.99 to 19.12), a positive toxicology test for cocaine (OR = 5.92; 2.60 to 13.50) or marijuana (OR = 3.52; 1.85 to 6.73), and 4 aberrant drug behaviors (OR = 11.48; 6.13 to 21.48). The final model for opioid use disorders was limited to aberrant behaviors (OR = 48.27; 13.63 to 171.04) as the other variables dropped out of the model.

Perspective

This study found that the frequency of opioid use disorders was 4 times higher in patients receiving opioid therapy compared with general population samples (3.8% vs 0.9%). The study also provides quantitative data linking aberrant drug behaviors to opioid use disorders.

 Department of Family Medicine, University of Wisconsin, Madison, Wisconsin.

 University of British Columbia, Vancouver, British Columbia, Canada.

Corresponding Author InformationAddress reprint requests to Dr. Michael Fleming, Department of Family Medicine, University of Wisconsin, Madison, 777 S. Mills Street, Madison, WI 53715.

 This study was supported by NIDA grant R01 DA013686. There were no pharmaceutical resources used in this study. None of the authors received consultation fees or have investments in pharmaceutical companies.

PII: S1526-5900(07)00630-X

doi:10.1016/j.jpain.2007.02.432


View previous. 10 of 13 View next.